Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G0ER
|
|||
| Former ID |
DIB004901
|
|||
| Drug Name |
DWJ-208
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Phase 1 | [1] | |
| Neuropathic pain [ICD-11: 8E43.0] | Phase 1 | [1] | ||
| Pain [ICD-11: MG30-MG3Z] | Investigative | [2] | ||
| Company |
Daewoong Pharmaceutical Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.7 (SCN9A) | Target Info | Antagonist | [1] |
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.